EP1937851A4 - Methods and compositions for generating bioactive assemblies of increased complexity and uses - Google Patents
Methods and compositions for generating bioactive assemblies of increased complexity and usesInfo
- Publication number
- EP1937851A4 EP1937851A4 EP06785922A EP06785922A EP1937851A4 EP 1937851 A4 EP1937851 A4 EP 1937851A4 EP 06785922 A EP06785922 A EP 06785922A EP 06785922 A EP06785922 A EP 06785922A EP 1937851 A4 EP1937851 A4 EP 1937851A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- increased complexity
- bioactive assemblies
- generating bioactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72829205P | 2005-10-19 | 2005-10-19 | |
US75119605P | 2005-12-16 | 2005-12-16 | |
US78233206P | 2006-03-14 | 2006-03-14 | |
US11/389,358 US7550143B2 (en) | 2005-04-06 | 2006-03-24 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
PCT/US2006/010762 WO2006107617A2 (en) | 2005-04-06 | 2006-03-24 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US11/391,584 US7521056B2 (en) | 2005-04-06 | 2006-03-28 | Stably tethered structures of defined compositions with multiple functions or binding specificities |
PCT/US2006/012084 WO2006107786A2 (en) | 2005-04-06 | 2006-03-29 | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
PCT/US2006/025499 WO2007046893A2 (en) | 2005-10-19 | 2006-06-29 | Methods for generating bioactive assemblies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1937851A2 EP1937851A2 (en) | 2008-07-02 |
EP1937851A4 true EP1937851A4 (en) | 2010-08-25 |
Family
ID=40666724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06785922A Withdrawn EP1937851A4 (en) | 2005-10-19 | 2006-06-29 | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1937851A4 (en) |
JP (1) | JP5231231B2 (en) |
AU (1) | AU2006302848C1 (en) |
CA (1) | CA2607056C (en) |
WO (1) | WO2007046893A2 (en) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
US8034352B2 (en) * | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
US8491914B2 (en) | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
US8481041B2 (en) | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
WO2009126558A1 (en) * | 2008-04-10 | 2009-10-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology |
WO2012024223A2 (en) * | 2010-08-17 | 2012-02-23 | Immunomedics, Inc. | Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
CN101138558B (en) * | 2007-09-13 | 2010-08-25 | 汕头大学医学院 | Pentamidine and death domain receptor ligand united application |
US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
JP5685529B2 (en) | 2008-06-13 | 2015-03-18 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダProyecto De Biomedicina Cima, S.L. | Complexes for the administration of compounds having biological activity |
AU2009282830B2 (en) | 2008-08-20 | 2013-11-28 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) vaccines for cancer therapy |
US9198952B2 (en) | 2008-09-22 | 2015-12-01 | The Brigham And Women's Hospital, Inc. | Compositions of and methods of using ligand dimers |
WO2010063865A1 (en) | 2008-12-03 | 2010-06-10 | Proyecto De Biomedicina Cima, S.L. | Use of phenol-soluble modulins for vaccine development |
WO2010091324A1 (en) * | 2009-02-06 | 2010-08-12 | Western States Biopharmaceuticals, Inc. | Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members |
US8535477B2 (en) | 2009-02-21 | 2013-09-17 | Sofradim Production | Medical devices incorporating functional adhesives |
EP2258398A1 (en) | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin-amyloid peptide conjugates and uses thereof |
CN102481348A (en) * | 2009-08-31 | 2012-05-30 | Ibc药品公司 | Bispecific immunocytokine dock-and-lock (DNL) complexes and therapeutic use thereof |
IN2012DN01662A (en) * | 2009-08-31 | 2015-06-05 | Immunomedics Inc | |
WO2011029980A1 (en) | 2009-09-11 | 2011-03-17 | Proyecto De Biomedicina Cima, S.L. | Therapeutic compositions for the treatment of hpv-induced diseases |
WO2011056721A2 (en) * | 2009-11-05 | 2011-05-12 | Center For Molecular Medicine And Immunology | Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines |
CA2782398C (en) * | 2009-12-09 | 2017-09-26 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
AU2010328136B2 (en) | 2009-12-09 | 2016-02-25 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
US10822396B2 (en) | 2009-12-15 | 2020-11-03 | MuHyeon CHOE | Repeat-chain for the production of dimer, multimer, multimer complex and super-complex |
EP2518078B1 (en) * | 2009-12-15 | 2020-05-20 | Choe, Muhyeon | Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an affinity domain of a type specifically binding to protein monomers |
CA2787074A1 (en) * | 2010-01-19 | 2011-07-28 | Immunomedics, Inc. | Novel antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
EP2555788B1 (en) | 2010-03-24 | 2017-10-11 | Massachusetts Institute of Technology | NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY. |
AU2011276443A1 (en) | 2010-06-29 | 2013-01-31 | Covidien Lp | Microwave-powered reactor and method for in situ forming implants |
EP2588153A2 (en) | 2010-07-01 | 2013-05-08 | Sofradim Production | Medical device with predefined activated cellular integration |
CN103328001B (en) * | 2010-11-03 | 2017-02-15 | Ibc药品公司 | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
CN103160513B (en) * | 2011-12-16 | 2015-07-01 | 中国医学科学院基础医学研究所 | MUC1 protein nucleic acid aptamer, complex, composition and purposes thereof |
EP2606897A1 (en) | 2011-12-22 | 2013-06-26 | Laboratorios Del. Dr. Esteve, S.A. | Methods and compositions for the treatment of diseases caused by enveloped viruses |
ES2672974T3 (en) | 2012-06-01 | 2018-06-19 | Ibc Pharmaceuticals, Inc. | Multimeric complexes with improved in vivo stability, improved pharmacokinetics and efficacy |
CN102703453B (en) * | 2012-06-13 | 2013-10-30 | 江南大学 | DNA aptamer specifically recognizing streptomycin and application of DNA aptamer |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US9315567B2 (en) | 2012-08-14 | 2016-04-19 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
ITRM20130138A1 (en) | 2013-03-07 | 2014-09-08 | Consiglio Nazionale Ricerche | ASSEMBLED INCLUDING A LIGHT ABSORBER IN THE INFRARED NEIGHBOR ENTITLELY TIED TO AN INHIBITOR OF THE CARBON DIVE |
US9775928B2 (en) | 2013-06-18 | 2017-10-03 | Covidien Lp | Adhesive barbed filament |
US9416197B2 (en) | 2013-11-01 | 2016-08-16 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease |
FR3017714A1 (en) * | 2014-02-18 | 2015-08-21 | Biomerieux Sa | METHOD AND KIT FOR DETERMINING THE PROBABILITY FOR A PATIENT TO EVOLVE TO A SEVERE DENGUE |
US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
CN113549153A (en) | 2014-05-29 | 2021-10-26 | 宏观基因有限公司 | Trispecific binding molecules and methods of use thereof |
AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
CN104558174A (en) * | 2015-01-29 | 2015-04-29 | 东南大学 | Testosterone-orientated specific nano-antibody and application thereof |
IL297418B2 (en) | 2015-02-18 | 2023-11-01 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
IL287500B2 (en) | 2015-04-21 | 2023-12-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
CN107614515B (en) | 2015-05-28 | 2022-03-22 | 免疫医疗公司 | T20 construct for anti-HIV (human immunodeficiency Virus) therapy and/or vaccine |
TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
KR20180034588A (en) | 2015-07-30 | 2018-04-04 | 마크로제닉스, 인크. | PD-1-binding molecules and methods for their use |
WO2017062619A2 (en) | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
EP3363447A4 (en) * | 2015-10-12 | 2019-07-03 | Industry - University Cooperation Foundation Hanyang University | Adenovirus complex for gene transfer and gene therapy |
WO2017094897A1 (en) * | 2015-12-04 | 2017-06-08 | 全薬工業株式会社 | Anti-il-17 aptamer having improved retention in blood |
CR20180318A (en) | 2015-12-14 | 2018-09-19 | Macrogenics Inc | BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME |
US11007251B2 (en) | 2015-12-17 | 2021-05-18 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
UY37127A (en) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | MOLECULES OF UNION TO ROR1, AND METHODS OF USE OF THE SAME |
US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
JP7281795B2 (en) | 2016-04-07 | 2023-05-26 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
MY198114A (en) | 2016-04-15 | 2023-08-04 | Macrogenics Inc | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
EP3558368A4 (en) | 2016-12-23 | 2020-12-30 | MacroGenics, Inc. | Adam9-binding molecules, and methods of use thereof |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
CN109771658B (en) * | 2017-11-14 | 2021-12-10 | 博瑞生物医药(苏州)股份有限公司 | Targeted multi-arm conjugates |
RU2020122822A (en) | 2017-12-12 | 2022-01-13 | Макродженикс, Инк. | BISPECIFIC CD16 BINDING MOLECULES AND THEIR USE IN THE TREATMENT OF DISEASES |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
KR102101561B1 (en) * | 2018-07-25 | 2020-04-20 | 가톨릭대학교 산학협력단 | Angiogenesis target constrast medium and a method for producing the same |
EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
EP4175650A1 (en) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
CN112156194B (en) * | 2020-09-29 | 2023-01-24 | 中国工程物理研究院核物理与化学研究所 | Removing method 177 Method for endotoxin in Lu solution |
WO2022108627A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030198956A1 (en) * | 2002-02-21 | 2003-10-23 | Lee Makowski | Staged assembly of nanostructures |
US20030232420A1 (en) * | 2002-05-03 | 2003-12-18 | Andreas Braun | Kinase anchor protein muteins, peptides thereof and related documents |
WO2006107617A2 (en) * | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
WO2007075270A2 (en) * | 2005-12-16 | 2007-07-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8501219A (en) * | 1985-04-29 | 1986-11-17 | Stichting Vrienden Van De Stic | IMMUNOLOGICAL COMPLEX, ITS PREPARATION AND APPLICATION. |
US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
ATE460946T1 (en) * | 1998-06-22 | 2010-04-15 | Immunomedics Inc | USE OF BISPECIFIC ANTIBODIES IN DIAGNOSIS AND THERAPY |
US7060506B2 (en) * | 2000-01-31 | 2006-06-13 | Cyclacel, Ltd. | Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides |
WO2004043563A2 (en) * | 2002-11-05 | 2004-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of isolation of active compounds and activated targets |
AU2004211481A1 (en) * | 2003-02-13 | 2004-08-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof |
-
2006
- 2006-06-29 CA CA2607056A patent/CA2607056C/en active Active
- 2006-06-29 WO PCT/US2006/025499 patent/WO2007046893A2/en active Application Filing
- 2006-06-29 EP EP06785922A patent/EP1937851A4/en not_active Withdrawn
- 2006-06-29 JP JP2008536564A patent/JP5231231B2/en active Active
- 2006-06-29 AU AU2006302848A patent/AU2006302848C1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030198956A1 (en) * | 2002-02-21 | 2003-10-23 | Lee Makowski | Staged assembly of nanostructures |
US20030232420A1 (en) * | 2002-05-03 | 2003-12-18 | Andreas Braun | Kinase anchor protein muteins, peptides thereof and related documents |
WO2006107617A2 (en) * | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
WO2007075270A2 (en) * | 2005-12-16 | 2007-07-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
Non-Patent Citations (15)
Title |
---|
BANKY P ET AL: "Dimerization/docking domain of the type Ialpha regulatory subunit of cAMP-dependent protein kinase. Requirements for dimerization and docking are distinct but overlapping.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 DEC 1998, vol. 273, no. 52, 25 December 1998 (1998-12-25), pages 35048 - 35055, XP002555878, ISSN: 0021-9258 * |
CHANG CHIEN-HSING ET AL: "The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 SEP 2007 LNKD- PUBMED:17875793, vol. 13, no. 18 Pt 2, 15 September 2007 (2007-09-15), pages 5586s - 5591s, XP009112546, ISSN: 1078-0432, DOI: 10.1158/1078-0432 * |
CHIEN-HSING CHANG ET AL: "A New Method to Produce MonoPEGylated Dimeric Cytokines Shown with Human Interferon-[alpha]2b", BIOCONJUGATE CHEMISTRY, vol. 20, no. 10, 21 October 2009 (2009-10-21), pages 1899 - 1907, XP055022032, ISSN: 1043-1802, DOI: 10.1021/bc9001773 * |
DEYEV S M ET AL: "Design of multivalent complexes using the barnase-barstar module", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 21, no. 12, 1 December 2003 (2003-12-01), pages 1486 - 1492, XP002372739, ISSN: 1087-0156 * |
EDMUND A ROSSI ET AL: "Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics", vol. 68, no. 20, 15 October 2008 (2008-10-15), pages 8384 - 8392, XP002698652, ISSN: 0008-5472, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/68/20/8384> DOI: 10.1158/0008-5472.CAN-08-2033 * |
GOLDENBERG DAVID M ET AL: "Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting.", JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE JAN 2008 LNKD- PUBMED:18077530, vol. 49, no. 1, January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185 * |
NEWLON M G ET AL: "The molecular basis for protein kinase A anchoring revealed by solution NMR.", NATURE STRUCTURAL BIOLOGY MAR 1999, vol. 6, no. 3, March 1999 (1999-03-01), pages 222 - 227, XP002555877, ISSN: 1072-8368 * |
OYEN O ET AL: "Human testis cDNA for the regulatory subunit RIIalpha of CAMP-dependent protein kinase encodes an alternate amino-terminal region", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 246, no. 1-2, 27 March 1989 (1989-03-27), pages 57 - 64, XP025652754, ISSN: 0014-5793, [retrieved on 19890327] * |
PLUCKTHUN A ET AL: "New protein engineering approaches to multivalent and bispecific antibody fragments", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 2, 1 June 1997 (1997-06-01), pages 83 - 105, XP004126672, ISSN: 1380-2933 * |
ROSSI E A ET AL: "Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 10, PART 2, 1 September 2003 (2003-09-01), pages 3886S - 3896S, XP002259779, ISSN: 1078-0432 * |
ROSSI EDMUND A ET AL: "A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.", CANCER RESEARCH 1 OCT 2010 LNKD- PUBMED:20876805, vol. 70, no. 19, 1 October 2010 (2010-10-01), pages 7600 - 7609, ISSN: 1538-7445 * |
ROSSI EDMUND A ET AL: "CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.", BLOOD 29 OCT 2009 LNKD- PUBMED:19710501, vol. 114, no. 18, 29 October 2009 (2009-10-29), pages 3864 - 3871, XP055215756, ISSN: 1528-0020, DOI: 10.1182/blood-2009-06-228890 * |
SHARKEY ROBERT M ET AL: "Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS FEB 2010 LNKD- PUBMED:20187791, vol. 25, no. 1, February 2010 (2010-02-01), pages 1 - 12, ISSN: 1557-8852 * |
SHARKEY ROBERT M ET AL: "Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.", CANCER RESEARCH 1 JUL 2008 LNKD- PUBMED:18593929, vol. 68, no. 13, 1 July 2008 (2008-07-01), pages 5282 - 5290, XP055273512, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-08-0037 * |
SHARKEY ROBERT M ET AL: "Optimizing bispecific antibody pretargeting for use in radioimmunotherapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 10, 1 September 2003 (2003-09-01), pages 3897S - 3913S, XP009099022, ISSN: 1078-0432 * |
Also Published As
Publication number | Publication date |
---|---|
AU2006302848A1 (en) | 2007-04-26 |
JP5231231B2 (en) | 2013-07-10 |
WO2007046893A2 (en) | 2007-04-26 |
WO2007046893A3 (en) | 2009-04-23 |
CA2607056C (en) | 2015-11-24 |
CA2607056A1 (en) | 2007-04-26 |
JP2009517337A (en) | 2009-04-30 |
AU2006302848B2 (en) | 2012-02-23 |
AU2006302848C1 (en) | 2012-08-02 |
EP1937851A2 (en) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1937851A4 (en) | Methods and compositions for generating bioactive assemblies of increased complexity and uses | |
EP1940423A4 (en) | Tissue engineering methods and compositions | |
PL1845803T3 (en) | Method for the prepration of spray-dried compositions and their uses | |
EP1973986A4 (en) | Bioactive complex compositions and methods of use thereof | |
IL192098A (en) | Compositions and methods for producing them | |
AP2465A (en) | Terpene-containing compositions and methods of making and using them | |
EP1895838A4 (en) | Compositions and methods | |
GB0522287D0 (en) | Method and compositions | |
IL186973A0 (en) | Compositions and methods for treatment for neoplasms | |
PL3398606T3 (en) | Microalgae-derived compositions for improving the health and appearance of skin | |
EP1744744A4 (en) | Bioactive compounds and methods of uses thereof | |
EP1899364A4 (en) | Compositions and methods for immunomodulation in an organism | |
IL191072A0 (en) | Therapeutic compositions and methods | |
EP1968526A4 (en) | Foamable dental compositions and methods | |
IL196465A0 (en) | Compositions and methods for the treatment of mucositis | |
IL190520A0 (en) | Compositions and methods for treatment of autoimmune | |
EP1937075A4 (en) | Synergistic composition and method of use | |
GB0524927D0 (en) | Compositions and method | |
GB0520930D0 (en) | Composition and method of use | |
GB0504657D0 (en) | Compositions and methods of treatment | |
GB0511235D0 (en) | Compositions and method | |
GB0501348D0 (en) | Compositions and methods | |
EP2046109A4 (en) | Photosyntheticorganisms and compositions and methods of generating same | |
EP1898956A4 (en) | Anti-tumoral compositions and methods | |
IL196588A0 (en) | Photosyntheticorganisms and compositions and methods of generating same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071018 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
R17D | Deferred search report published (corrected) |
Effective date: 20090423 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/00 20060101ALI20090623BHEP Ipc: C07K 16/46 20060101ALI20090623BHEP Ipc: A61K 39/395 20060101ALI20090623BHEP Ipc: A61K 38/16 20060101ALI20090623BHEP Ipc: A61K 31/00 20060101ALI20090623BHEP Ipc: C07K 19/00 20060101ALI20090623BHEP Ipc: C07K 17/00 20060101ALI20090623BHEP Ipc: A61K 103/00 20060101ALI20090623BHEP Ipc: A61K 51/00 20060101AFI20090623BHEP Ipc: C07K 14/00 20060101ALI20090623BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100722 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/48 20060101ALI20100716BHEP Ipc: C07K 16/28 20060101AFI20100716BHEP |
|
17Q | First examination report despatched |
Effective date: 20110727 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180412 |